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The human immunodeficiency virus (HIV-1) disseminates in the body and is found in
several organs and tissues. Although HIV-1 mainly targets both CD4+ T lymphocytes
and macrophages, it has contrasting effects between these cell populations. HIV-1
infection namely reduces the viability of CD4+ T cells, whereas infected macrophages
are long-lived. In addition, the migration of T cells is reduced by the infection, whereas
HIV-1 differentially modulates the migration modes of macrophages. In 2-dimensions (2D)
assays, infected macrophages are less motile compared to the control counterparts. In
3D environments, macrophages use two migration modes that are dependent on the
matrix architecture: amoeboid and mesenchymal migration. HIV-1-infected macrophages
exhibit a reduced amoeboid migration but an enhanced mesenchymal migration, via
the viral protein Nef. Indeed, the mesenchymal migration involves podosomes, and Nef
stabilizes these cell structures through the activation of the tyrosine kinase Hck, which in
turn phosphorylates the Wiskott–Aldrich syndrome protein (WASP). WASP is a key player
in actin remodeling and cell migration. The reprogramed motility of infected macrophages
observed in vitro correlates in vivo with enhanced macrophage infiltration in experimental
tumors in Nef-transgenic mice compared to control mice. In conclusion, HIV infection
of host target cells modifies their migration capacity; we infer that HIV-1 enhances
virus spreading in confined environments by reducing T cells migration, and facilitates
virus dissemination into different organs and tissues of the human body by enhancing
macrophage mesenchymal migration.
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Introduction
The biology and pathogenesis of HIV infection has been largely studied since the discovery of
the virus in 1983. Although the molecular mechanisms involved in virus internalization and
replication within its host cells are well described, other key mechanisms of HIV pathogenesis
and progression to AIDS, including virus dissemination, are less characterized. During unprotected
sexual intercourse,HIV-1 ismainly transmitted through genital and/or rectalmucosal sites, resulting
in rapid infection of target cells and access to the bloodstream to ultimately reach lymph nodes at
different sites, including the gut, spleen, and lungs, as well as the brain (1). Different mechanisms
are involved in HIV-1 dissemination, such as a short period of time when cell-free virus circulates in
body fluids and a phase in which the virus can be transported by carrier cells. HIV-1 targets CD4+
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T lymphocytes and cells from the mononuclear phagocyte lin-
eage (i.e., monocytes, macrophages, and dendritic cells). The
virus developed several strategies to disseminate within the
human body using host cells. One of the well-documented strate-
gies is cell-to-cell transfer. For instance, T-cell-to-T-cell and
macrophage-to-T-cell transfer of the virus is an efficient way
for the virus to spread locally (2–6). Another strategy consists
in manipulating host cell migration, as shown previously for
CD4+ T lymphocytes (7), and more recently, for macrophages
(8). Regarding HIV-infected T cells, they are able to migrate
within lymph nodes favoring virus spreading by a cell-to-cell
transfermechanism (7). Blocking the egress of T cells, or any other
cell from the lymph nodes into efferent lymph vessels, decreases
viremia. However, it is not established whether this process could
account for virus spreading in body tissues (1, 7). Of note, T cells
rapidly die after infection in patients. By contrast, macrophages
are able to survive to infection and they have the ability to migrate
into all body tissues. They are thus suspected to be a target of
great interest for HIV to spread. We have recently shown that
macrophage migration is reprogramed on infection (8), a mecha-
nism that could contribute to HIV-1 dissemination in the body.
Despite the fact that HIV-1 or HIV-1 proteins are well known
to induce a “bystander” effect on macrophage migration through
the concertedmodulation of cytokines/chemokines (9–13); in this
review, we focus on the intracellular molecular impact of HIV-1
to control the migration of host cells.
HIV-1 Nef Regulates Both T Cell and
Macrophage Migration
The migration of CD4+ T lymphocytes is inhibited by HIV-1
infection both in vitro and in lymph nodes (7, 14–18). The HIV-
1 protein Nef is responsible for the inhibition of T cell migra-
tion in vitro both in 2D and in 3D environments (14–18). In
addition, Vpu is also an important factor for impaired migration
of infected T lymphocytes toward CCL19 (19). HIV-1 infection
also markedly affects the migration of human macrophages, as
their 2D migration is inhibited and their 3D migration is affected
(8). Of note, the 3D migration of macrophages is a complex
phenomenon that involves two distinct modes dictated by the
extracellular matrix (ECM) architecture (20). In environments
with high porosity, macrophages use the amoeboid mode that
is characterized by a round cell morphology, the involvement of
the ROCK signaling pathway, and a high velocity of cells that
squeeze themselves into matrix pores (20). In environments with
low porosity, macrophages use the mesenchymal mode that is
distinguished by an elongated and protrusive cell morphology, a
directed motion with moderate velocity, and the requirement of
proteases (20). In the latter case, matrix proteolysis is associated
with its ingestion and compaction that allow macrophages to
create paths (8, 20–28). In marked contrast with macrophages, all
other leukocytes only use the amoeboid mode (29). Interestingly,
amoeboid migration is inhibited in HIV-1 infected macrophages
while the mesenchymal mode is enhanced (8). These effects of
HIV-1 on 2D and 3D macrophage migration are all mediated
by Nef. Indeed, the infection of macrophages with a Nef-deleted
virus (Δnef HIV-1) lacks all these migration defects, and the
targeted expression of Nef in macrophages recapitulates them (8).
Therefore, Nef is a master regulator by which HIV-1modulates all
form of motility used by host cells.
Among pathological contexts, malignant tumors represent a
tissue model to study the macrophage 3D migration. Indeed,
tumor formation triggers the immediate recruitment from tumor-
associated macrophages (TAM) that originate of blood mono-
cytes (30). We used this model to assess the impact of HIV-1 on
macrophage migration and tissue infiltration to complement our
in vitro observations using different 3D environments. In Nef-
transgenic (Tg) mice, a higher number of TAM is observed com-
pared to those from littermate non-Tgmice. This result may seem
surprising since in macrophages Nef inhibits amoeboid and 2D
migration and only enhances mesenchymal migration, but it can
be reconciliated if the architectural properties ofmalignant tumors
are taken into consideration. Indeed, malignant tumors are dense
and rigid (31–33), which likely favor the use of the mesenchymal
mode of migration by macrophages. Moreover, we have recently
observed that mesenchymal migration is involved in TAM infil-
tration [Ref. (21) and Gui et al. manuscript in preparation]. Thus,
Nef seems to favor in vivomacrophage infiltration in dense tissues,
such as malignant tumors, possibly by enhancing the mesenchy-
mal mode of migration. In the light of these data, we propose
that in porous tissues in which macrophages use the amoeboid
mode, Nef-expressing macrophages would be less numerous than
control macrophages. In other words, HIV-infected macrophages
would accumulate in dense tissues and poorly infiltrate porous
tissue regions, allowing virus dissemination preferentially in cer-
tain body tissues or in certain area of tissues with heterogeneous
architectures. In infected patients andmacaques, macrophages are
found in several tissues including kidney, liver, gastrointestinal
tract mucosa, and brain (34–37). Interestingly, in Nef Tg mice,
we observed a high number of macrophages in kidney, liver,
and gut tissues as compared to control mice. To better under-
stand these results, it would be informative to characterize the
biophysical properties of tissues massively infiltrated by infected
macrophages and compare them to those that lack this type of cell
accumulation in order to establish a correlation between tissue
characteristics and the infiltration of infected macrophages. It
would be also interesting to explore whether macrophages are
more abundant in the brain from Nef Tg mice, as this critical
organ is highly infiltrated by macrophages in both HIV+ patients
and SIV-infected primates (36). This is an important question
since the presence of infected macrophages is highly correlated to
neurological dysfunction leading to HIV-1-associated dementia
(36, 38–40).
Finally, Nef is also known to inhibit the migration of T cells
in vitro and block their extravasation through endothelial venules
in vivo (1, 17). Within lymph nodes, the migration of infected
lymphocytes is impaired favoring cell-to-cell contact and possibly
resulting in a higher incidence of virus transfer among resident
cells (7). In fact, the high cellular promiscuity likely allows HIV-1
to be transmitted both via the cis-type and trans-type infection
using the formation of virological synapses, as mainly reported
in vitro (1). Since macrophages exhibit a long-lasting survival,
and display a capacity to efficiently migrate and infiltrate all body
tissues, we will now focus on the migration mechanisms of the
HIV-1-infected macrophages.
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HIV-1 Nef is an Actin Modulator that
Targets Podosomes
HIV-1 Nef triggers F-actin remodeling in all cell targets (e.g.,
T lymphocytes, macrophages, and dendritic cells) (8, 41, 42).
Depending on the cell type, Nef can cause depolymerization or
polymerization of F-actin (42). In macrophages, Nef induces the
formation of F-actin nanotubes to transfer viral particles to B
cells (6). In T cells, Nef effects on the cytoskeleton dynamics, and
thus help the virus to enter into cells and to transfer into another
lymphocyte by the formation of virological synapses, prevent the
formation of actin ruffles, and trigger filopodium-like protrusions
(15, 18, 42). Cell migration is an actin-dependent mechanism.
HIV-1/Nef has pleiotropic effects on HIV-1-infected and Nef-
transfected T cell, including its impact on the actin cytoskeleton
(42–44). Indeed, Nef is known to inhibit T cell migration by
altering the phosphorylation/dephosphorylation of cofilin, which
triggers actin filament disassembly (17, 18). Nevertheless, there
are no differences in the status of cofilin phosphorylation in
wtHIV-1, ΔnefHIV-1 or uninfected macrophages. Consequently,
we infer that the cofilin pathway is not involved in the inhibition
of macrophage amoeboid movement.
Podosomes are constitutively formed in few cell types, includ-
ing macrophages, immature dendritic cells, and osteoclasts when
adhering on stiff substrates. These structures are involved in cell
adhesion, proteolytic degradation of the ECM, mechanosensing,
andmesenchymalmigration. They are not formed in cells that use
the amoeboid migration, such as T lymphocytes (8, 20–27, 29).
Whenmacrophages are plated on coverslips, podosomes assemble
at the ventral plasma membrane and are oriented perpendicu-
larly to the substrate. They are constituted of an F-actin core
surrounded by a ring of adhesion proteins, and concentrate most
of the cellular F-actin. The organization of podosomes into super-
structures called “podosome rosettes” is related to an increase in
ECM degradation (45, 46) (Figure 1). In HIV-1-infected cells,
podosomes become bigger, they assemble into podosome rosettes
and the ECM degradation is enhanced, phenomena which are
not observed in macrophages infected with ΔnefHIV-1. In Nef-
expressing macrophages, podosomes are more stable, their life
span is doubled, and they degrade very actively the ECM, possibly
as a result of their increased lifetime and their rosette orga-
nization. Interestingly, Nef accumulates in the podosome area,
suggesting that it could interact with a podosome effector regu-
lating the stability of these cell structures. In 3D environments,
podosomes assemble at the tip of cell protrusions; they are called
3D podosomes (28). Interestingly, HIV-1-infected cells and Nef-
expressing macrophages form more 3D podosomes than con-
trol cells (8). The regulation of podosomes by Nef can explain
two aspects of the modified migration of macrophages by HIV-
1 (Figure 2). First, podosomes that are adhesion cell structures
are more stable and bigger, thus explaining the increased cell
adhesion observed in HIV-1-infected macrophages (8). Actually,
modifications in cell adhesion are known to result in altered 2D
cell motility (47, 48). For example, the maturation of dendritic
cells, which induces the dissolution of podosomes, allows these
cells to undergo the transition from an adhesive to a highly
migratory phenotype (49, 50). By contrast, increased cell adhesion
FIGURE 1 | Human macrophage podosomes in 2D environments. On
2D surfaces, podosomes stained for F-actin (red) are scattered (upper panels)
or organized as rosettes (lower panels). Both individual podosomes and
podosomes organized as rosettes are involved in matrix degradation, as
shown by dark holes (upper panels, arrows) and a track (lower panels) in the
FITC-gelatin (blue) coating. Activation of some podosome proteins favors the
organization of podosomes as rosettes and, consequently, increases
proteolysis of the extracellular matrix (45, 46).
by more stable podosomes should decrease 2D migration of
HIV-1-infected macrophages. Second, 3D mesenchymal migra-
tion correlates with podosome stability and an increase in ECM
proteolytic activity (45, 46), two parameters increased by HIV-1
infection (8). Therefore, by affecting podosomes, HIV-1 reduces
the macrophage 2D migration and enhances 3D mesenchymal
migration. This is the first pathogen known to target podosomes
to control the migration of host cells.
Nef/Hck Interaction: A Potential
Pharmacological Target
Nef modulates the function of several proteins also described
to localize at podosomes, including Wiskott–Aldrich syndrome
protein (WASP), Hck, paxillin, and cofilin (18, 51–53). Hck
and WASP are key effectors of the mesenchymal migration in
macrophages (25, 45, 54). Hck is a tyrosine kinase of the Src
family specifically expressed in phagocytes. Hck controls sev-
eral processes, such as receptor signaling, lysosome trafficking,
podosome stability, and organization into podosome rosettes, as
well as proteolytic activity of podosomes (45, 55–57). Interest-
ingly, mesenchymalmigration is reduced inHck /  orWASP / 
macrophages, while Hck and WASP depletion have no effect on
amoeboid migration.
Among a plethora of host proteins, Nef interacts through
its poly-proline sequence with the SH3 domain of Src tyrosine
kinases (58). In macrophages, this interaction mediates activation
of Hck (53). In addition to the poly-proline sequence of Nef,
several other Nef domains are involved in podosome regulation
suggesting that other Nef effectors than Hck control podosomes.
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FIGURE 2 | By targeting podosomes, HIV-1 Nef inhibits 2D migration and enhances the 3D mesenchymal migration mode of macrophages. HIV-1
infection of macrophages increases the size and stability of podosomes, compared to non-infected cells. The molecular mechanisms responsible for this process
involve the interaction of the viral protein Nef with Hck, and WASP phosphorylation. Increase in podosome size correlates with (1) increase in cell adhesion and
inhibition of 2D migration and (2) increase in matrix degradation, enhancement of 3D mesenchymal migration and thus macrophage infiltration in tissues.
However, Hck appeared to be the main actor for enhancing
mesenchymal migration since this effect is abolished when Hck
is knocked-down in HIV-1-infected macrophages. These results
suggest that Hck plays distinct roles in mesenchymal migra-
tion controlling either podosome formation or protease release.
Actually, the p61Hck isoform is located at lysosomes and is
involved in the proteolytic activity of podosomes (55), which is
necessary for 3Dmesenchymal migration (20). In HIV-1-infected
macrophages, the phosphorylation of WASP is enhanced and
phosphorylatedWASP accumulates at podosomes of infected cells
in a Nef-dependent manner where it likely promotes the stability
of F-actin (8). Thus, Nef controls the migration of macrophages
by activating Hck, which in turn regulates the activity of WASP
to stabilize podosomes and enhance mesenchymal migration
(Figure 2).
The Nef/Hck axis mediates the increase in the mesenchymal
migration of infected macrophages and probably their deleteri-
ous accumulation in tissues. In addition to the already proposed
disruption of Nef/Hck interaction as a potential antiviral strat-
egy (59–63), we propose to target this interaction to specifically
restore themigration parameters of HIV-1-infectedmacrophages.
Although it is well established that Nef is essential for AIDS
pathogenesis, it is not currently targeted by antiviral therapeutic
strategies. The first Nef inhibitor described in the literature that
contains an optimized derivative of the SH3 domain of Hck,
alters Nef interactions with SH3-bearing proteins (63). Moreover,
small Nef-interacting proteins composed of a Nef-targeted SH3
domain fused to a sequence motif of the CD4 cytoplasmic tail
and combined with a prenylation signal formembrane association
have also been developed (61). Finally, Neffins have recently been
developed. They comprise an anti-Nef single-domain antibody
fused to part of the Hck SH3 domain (Neffins B6 and C1), inhibit
all key activities of Nef in T cells, and inhibit cell fusion and
modulation of podosomes in macrophages, two processes that
depend on Hck activation by Nef (64, 65). These observations
support the strategy to develop new antiviral drugs targeting
Nef/Hck interaction.
Hck: A Promising Pharmacological Target
to Limit Macrophage Tissue Infiltration
Althoughmacrophages play a key role in immune protection, they
also play detrimental roles in several diseases including cancer
and chronic inflammations. Elucidation of the migration modes
and mechanisms used by macrophages was a challenge of the
past decade, including the need to identify key migration players
for pharmacological inhibition. One example is Hck, a migration
effector that we postulate as a good target. Indeed, based on
several studies involving its deletion/depletion in macrophages,
Hck appears to be instrumental for podosome structure/function
and mesenchymal migration in vitro and in vivo (8, 21–27, 45,
57). Of note, Hck expression is restricted to phagocytes and thus
its pharmacological inhibition should not impact other cell types.
Furthermore, HIV-1 developed the strategy to activate Hck to
enhance the mesenchymal migration of macrophages (8), fur-
ther supporting Hck as a therapeutic target. Actually, the virus
teaches us how to control a migration mode that is involved in
macrophage infiltration in tumors (8, 21). Collectively, we believe
that targeting Hck might have strong implications in control-
ling the macrophage recruitment in cancer and possibly in other
diseases including AIDS.
Conclusion
HIV-1 is able to modify the migration of its main host cells
(T lymphocytes and macrophages) via Nef, which appears as
a key regulator of the migration of T cells and the different
modes of macrophage migration. This is a powerful pathogenic
strategy that could favor cell-to-cell spreading of the virus by
inhibiting T cell migration in lymph nodes and promoting virus
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dissemination through body tissues by enhancing macrophage
3D mesenchymal migration. Similarly to the actin-based
motility of bacteria employed by Listeria or Shigella, a
biological context that yielded major advances in the in-
depth knowledge of the actin polymerization machinery
(66), HIV-1 has similarly developed a strategy to exploit the
actin cytoskeleton and cell migration, and this way, reveals
substantial insights into molecular pathways regulating cell
migration.
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